कृपया अन्य खोज का प्रयास करें
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company’s lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Punit S. Dhillon | 42 | 2018 | Executive Chairman, President, CEO & Secretary |
Sukhwinder S. Rai | 53 | 2022 | Director |
Andrew James Schwab | 52 | 2023 | Director |
Paul A. Grayson | - | 2023 | Director |
Jeffrey Goldberg | - | - | Member of Clinical Advisory Board |
Margaret R. Dalesandro | 77 | 2020 | Independent Director |
Eduardo Munoz | - | 2021 | Member of Scientific Advisory Board |
Louis R. Pasquale | - | - | Member of Clinical Advisory Board |
Robert Ritch | - | - | Member of Clinical Advisory Board |
Giovanni Appendino | - | 2021 | Member of Scientific Advisory Board |
Praveen Tyle | 64 | 2021 | Independent Director |
Keith W. Ward | 54 | 2021 | Independent Director |
Deborah Charych | 58 | 2023 | Independent Director |
Annalisa Mary Jenkins | 59 | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है